ERT provided CT and MRI imaging services for a mid-sized pharmaceutical company running sequential Phase II and III studies on advanced unresectable dedifferentiated liposarcoma.
The Sponsor’s Challenge
The sponsor needed to incorporate multiple tumor assessment criteria into the image evaluation protocol , which significantly increased image reading complexity, turnaround time and cost challenges. They chose to use ERT’s purpose-built oncology image processing and analysis technology for software-guided radiologist reads.
ERT’s Purpose-Built Imaging Solution
By leveraging ERT imaging expertise and software-assisted tumor response evaluation technology, the sponsor could:
- Incorporate multiple tumor assessment criteria (e.g., RECIST, irRC, WHO, Lugano) into the IEP and imaging endpoints
- Generate efficacy data required for FDA submission, all while reducing the need for reader adjudication in pivotal trials
- Improve image evaluation turnaround time, reduce inter-reader discordance, drive reader-based errors to zero, and virtually eliminate image evaluation data queries